JP2025512466A - 抗可変ｍｕｃ１＊抗体およびその使用 - Google Patents

抗可変ｍｕｃ１＊抗体およびその使用 Download PDF

Info

Publication number
JP2025512466A
JP2025512466A JP2024560671A JP2024560671A JP2025512466A JP 2025512466 A JP2025512466 A JP 2025512466A JP 2024560671 A JP2024560671 A JP 2024560671A JP 2024560671 A JP2024560671 A JP 2024560671A JP 2025512466 A JP2025512466 A JP 2025512466A
Authority
JP
Japan
Prior art keywords
muc1
antibody
mnc2
conjugate
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512466A5 (enExample
Inventor
バムダッド，シンシア
スマッジ，ブノワ
モエ，スコット
ジョン，トーマス
Original Assignee
ミネルバ バイオテクノロジーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミネルバ バイオテクノロジーズ コーポレーション filed Critical ミネルバ バイオテクノロジーズ コーポレーション
Publication of JP2025512466A publication Critical patent/JP2025512466A/ja
Publication of JP2025512466A5 publication Critical patent/JP2025512466A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2024560671A 2022-04-12 2023-04-11 抗可変ｍｕｃ１＊抗体およびその使用 Pending JP2025512466A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263330277P 2022-04-12 2022-04-12
US63/330,277 2022-04-12
PCT/US2023/065637 WO2023201234A2 (en) 2022-04-12 2023-04-11 Anti-variable muc1* antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025512466A true JP2025512466A (ja) 2025-04-17
JP2025512466A5 JP2025512466A5 (enExample) 2026-04-21

Family

ID=88330347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560671A Pending JP2025512466A (ja) 2022-04-12 2023-04-11 抗可変ｍｕｃ１＊抗体およびその使用

Country Status (9)

Country Link
US (1) US12491259B2 (enExample)
EP (1) EP4319822A4 (enExample)
JP (1) JP2025512466A (enExample)
KR (1) KR20250009592A (enExample)
CN (1) CN119317447A (enExample)
AU (1) AU2023253692A1 (enExample)
CA (1) CA3248038A1 (enExample)
IL (1) IL316221A (enExample)
WO (1) WO2023201234A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES
IL326916A (en) 2023-08-29 2026-05-01 Minerva Biotechnologies Corp Bacterial orthologs of NME7 and their uses
EP4684805A1 (en) * 2024-07-24 2026-01-28 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Selective antibody-drug conjugates for targeted cancer therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496542A (en) 1981-03-30 1985-01-29 Usv Pharmaceutical Corporation N-substituted-amido-amino acids
US20240390418A1 (en) 1997-09-04 2024-11-28 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
CA2360927C (en) 1999-01-23 2018-03-06 Minerva Biotechnologies Corporation Interaction of colloid-immobilized species with species on non-colloidal structures
JP5122705B2 (ja) 1999-01-25 2013-01-16 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
AU2001265403A1 (en) 2000-05-26 2001-12-11 Minerva Biotechnologies Corporation Metallocenes as signal-transducer for detection of chemical or biological events
CA2413884A1 (en) 2000-06-23 2002-01-03 Minerva Biotechnologies Corporation Rapid and sensitive detection of protein aggregation
JP2004512497A (ja) 2000-06-23 2004-04-22 ミナーヴァ・バイオテクノロジーズ・コーポレーション コロイドが固定された種と非コロイド構造上の種との相互作用
AU2002216614A1 (en) 2000-10-03 2002-04-15 Minerva Biotechnologies Corporation Electronic detection of interaction based on the interruption of flow
EP1336104B1 (en) 2000-11-01 2009-03-25 Minerva Biotechnologies Corporation Proteomics based drug comparison methods
EP1348034B1 (en) 2000-11-15 2016-07-20 Minerva Biotechnologies Corporation Oligonucleotide identifiers
US7700715B2 (en) 2000-11-27 2010-04-20 Minerva Biotechnologies Corporation Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
CA2459110A1 (en) 2001-08-31 2003-03-06 Cynthia C. Bamdad Affinity tag modified particles
CA2459584A1 (en) 2001-09-05 2003-03-13 Cynthia C. Bamdad Compositions and use thereof in the treatment of cancer
EP1425016B1 (en) 2001-09-05 2010-06-02 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
JP2007531505A (ja) 2002-11-27 2007-11-08 ミネルバ バイオオテクノロジーズ コーポレーション 癌（ｍｕｃ１）の診断および治療のための技術および組成物
AU2003300371A1 (en) 2002-12-20 2004-07-22 Minerva Biotechnologies Corporation Optical devices and methods involving nanoparticles
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20080064680A1 (en) 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
US8859495B2 (en) 2005-03-30 2014-10-14 Minerva Biotechnologies Corporation Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
US20090075926A1 (en) 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
EP2214485B1 (en) 2007-09-25 2016-07-20 Minerva Biotechnologies Corp. Methods for treatment of cancer
US20090092603A1 (en) 2007-09-25 2009-04-09 Bamdad Cynthia C Early diagnosis and treatment of drug resistance in muc1-positive cancer
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
JP2012504961A (ja) 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
KR20160017117A (ko) 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
MX2011013385A (es) 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
EP3228629A1 (en) 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
US20240247229A1 (en) 2011-10-17 2024-07-25 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
EP2768945B1 (en) 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
WO2013123084A1 (en) 2012-02-13 2013-08-22 Minerva Biotechnologies Corporation Method for detecting circulating fetal cells
WO2013152860A2 (en) 2012-04-11 2013-10-17 Dutalys Gmbh Improved antibody light chains
WO2014012115A2 (en) 2012-07-13 2014-01-16 Minerva Biotechnologies Corporation Method for inducing cells to less mature state
CA2880010A1 (en) 2012-07-24 2014-01-30 Minerva Biotechnologies Corporation Nme variant species expression and suppression
AU2013302620B2 (en) 2012-08-14 2018-08-02 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
CA2891566A1 (en) 2012-12-05 2014-06-12 Dutalys Gmbh Dual targeting
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
KR20210082547A (ko) 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법
US20160326263A1 (en) 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
EP4233536B1 (en) 2013-08-12 2025-12-31 Minerva Biotechnologies Corporation TUMOR GROWTH STIMULATION METHOD
CN106132992B (zh) 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US20170106046A1 (en) 2015-03-03 2017-04-20 Minerva Biotechnologies Corporation Method for diagnosing and treating cancer using naive state stem cell specific genes
EP3316682A4 (en) 2015-07-01 2019-01-23 Minerva Biotechnologies Corporation PROCESS FOR STRAIN CELL BASED ORGAN AND TISSUE AGENCY
EP3352566A4 (en) 2015-09-23 2019-07-31 Minerva Biotechnologies Corporation SCREENING METHOD FOR ACTIVE SUBSTANCES FOR DIFFERENTIATING STEM CELLS
WO2017180834A1 (en) 2016-04-13 2017-10-19 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
CA3039797A1 (en) 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
RU2746413C1 (ru) 2017-03-21 2021-04-13 Пептрон, Инк. Антитело, специфически связывающееся с muc1, и его применение
AU2018244449B2 (en) 2017-03-29 2024-07-11 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
WO2019104306A1 (en) 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
WO2019126357A1 (en) 2017-12-19 2019-06-27 Minerva Biotechnologies Corporation Agents for treating cancer and methods for identifying said agents
IL326873A (en) 2017-12-29 2026-04-01 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
WO2019165421A1 (en) 2018-02-26 2019-08-29 Minerva Biotechnologies Corporation Diagnostic methods using anti-muc1* antibodies
US20200405832A1 (en) 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
EP3794042B1 (en) * 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
UA130338C2 (uk) 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
AU2019396895B2 (en) * 2018-12-11 2025-09-11 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with PARP inhibitor
WO2020146902A2 (en) 2019-01-11 2020-07-16 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
JP7664045B2 (ja) 2019-03-06 2025-04-17 リガケム バイオサイエンシズ， インク． ヒトｄｌｋ１に対する抗体を含む抗体薬物コンジュゲート及びその使用
CA3085001C (en) 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
WO2020259258A1 (zh) 2019-06-28 2020-12-30 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
JP2022544543A (ja) 2019-08-15 2022-10-19 シルバーバック セラピューティックス インコーポレイテッド ベンザゼピンコンジュゲートの製剤およびその使用
CN114845740B (zh) 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
WO2021242935A1 (en) 2020-05-26 2021-12-02 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
JP2023530039A (ja) 2020-06-08 2023-07-12 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
EP4171592A4 (en) 2020-06-26 2024-07-31 Minerva Biotechnologies Corporation Methods for deriving dopaminergic neurons from pluripotent stem cells
WO2022015880A2 (en) * 2020-07-14 2022-01-20 Cue Biopharma, Inc. T-cell modulatory polypeptides with conjugation sites and methods of use thereof
CN116234828A (zh) 2020-07-29 2023-06-06 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES
IL316918A (en) 2022-05-09 2025-01-01 Minerva Biotechnologies Corp Chimeric antigen receptor and IL-18 receptor compositions and methods of using them
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
IL326916A (en) 2023-08-29 2026-05-01 Minerva Biotechnologies Corp Bacterial orthologs of NME7 and their uses
EP4587063A1 (en) 2023-10-11 2025-07-23 Minerva Biotechnologies Corporation Anti-muc1* antibody drug complexes and uses thereof

Also Published As

Publication number Publication date
WO2023201234A3 (en) 2023-11-30
CN119317447A (zh) 2025-01-14
AU2023253692A1 (en) 2024-11-14
US20250114471A1 (en) 2025-04-10
WO2023201234A2 (en) 2023-10-19
KR20250009592A (ko) 2025-01-17
EP4319822A2 (en) 2024-02-14
US12491259B2 (en) 2025-12-09
IL316221A (en) 2024-12-01
EP4319822A4 (en) 2024-10-16
CA3248038A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
JP7401126B2 (ja) 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
US20210163620A1 (en) Trispecific binding molecules against cancers and uses thereof
JP6063747B2 (ja) Ｐｓｍａ抗体薬物複合体
KR20240095316A (ko) Bcma 단일클론 항체 및 항체-약물 접합체
JP5925875B2 (ja) 抗体−薬剤コンジュゲート
US12491259B2 (en) Anti-variable MUC1* antibodies and uses thereof
KR20160047567A (ko) 조작된 항-dll3 접합체 및 사용 방법
CN118271442A (zh) 抗sez6l2抗体和抗体药物缀合物
TW202515620A (zh) 抗體－藥物偶聯物靶向治療前列腺癌和其他腫瘤
US20260137799A1 (en) Anti-muc1* antibody drug complexes and uses thereof
WO2023124963A1 (zh) 一种可逆反应减少的抗体-药物偶联物，其制备方法及应用
TW202509083A (zh) 抗體及其抗體－藥物偶聯物
CA3023088A1 (en) Novel anti-tnfrsf21 antibodies and methods of use
JP2018515457A (ja) カリケアマイシン構築物および使用方法
WO2024230755A1 (zh) 一种抗pdl1抗体-药物偶联物及应用
US20240091372A1 (en) Anti-doppel antibody drug conjugates
WO2024181570A1 (ja) 抗ｃｄ１３８抗体を含む抗体薬物複合体
WO2024230756A1 (zh) 一种抗表皮生长因子受体(egfr)抗体-药物偶联物及其应用
HK40102814A (en) Bcma monoclonal antibody-drug conjugate
HK1186110A (en) Psma antibody-drug conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260413